Synthesis of 2-(phenylazo)-5-ethoxypyridine (5-EtO-AZPY). 2-(Phenylazo)-5-
fluoropyridine (100.0 mg, 0.497 mmol) was dissolved in ethanol (20 mL) and an aqueous KOH solution was added (5 mol. equiv.). The mixture was heated to reflux for 18 h and the product was extracted with dichloromethane (20 mL) and washed with water (3 x 20 mL). The dichloromethane extract was dried over MgSO4, filtered, and the solvent was removed under reduced pressure. The crude product was recrystallised from a minimum amount of hot diethyl ether. Orange crystals were collected via vacuum filtration, washed with ice-cold diethyl ether and dried overnight in a vacuum desiccator. Yield: 78.1 mg (69%). 1 
Synthesis of [Os(η 6 -p-cym)(5-EtO-AZPY)I]CF3SO3 (1-I·CF3SO3).
[Os(η 6 -p-cym)I2]2 (50 mg, 43.2 µmol) was dissolved in ethanol (10 mL), and a solution of 2-(phenylazo)-5-ethoxypyridine (20.6 mg, 90.8 µmol) in ethanol (5 mL) was added drop-wise. The mixture was stirred for 18 h at ambient temperature, and ammonium triflate (72.3 mg, 0.43 mmol) was added. The mixture was concentrated under reduced pressure to ~3 S4 mL and placed in a freezer overnight. A dark crystalline precipitate formed, which was collected via vacuum filtration and washed with ice-cold ethanol (2 x 1 mL), diethyl ether (2 x 5 mL), and dried overnight in a vacuum desiccator. Yield: 66.8 mg (93%). 1 Complex 1-I·CF3SO3 was used in studies of the aqueous chemistry of 1-I rather than 1-I·PF6 because of its improved aqueous solubility. The counter anion has no effect on the anticancer activity or chemical reactivity of the complex.
Synthesis of [Os(η 6 -p-cym)(5-EtO-AZPY)OH]PF6 (1-OH·PF6).
To a stirred solution of [Os(η 6 -p-cym)Cl2]2 (100 mg, 126.5 µmol) in methanol (3 mL), silver nitrate (58.87 g/L, 1459 µL) in water was added. The mixture turned yellow and a white precipitate formed, which was removed via filtration. A solution of 5-EtO-AZPY (60.4 mg, 265.6 µmol) in methanol (5 mL) was added drop-wise to the yellow solution and it turned brown. The mixture was stirred for 18 h at ambient temperature, then ammonium hexafluorophosphate (206.2 mg, 1.26 mmol) was added. The product was extracted with DCM (10 mL) and washed with water (2 x 10 mL). DCM was removed under reduced pressure and the product was re-dissolved in a minimum amount of methanol (~2 mL), and placed in a freezer overnight. A brown precipitate formed, which was collected via vacuum filtration then washed with ice-cold ethanol (2 x 1 mL), diethyl ether (2 x 5 mL), and dried overnight in a vacuum desiccator. Yield: 160.6 mg (89%). These were synthesized and characterised as described previously. [2] Crystal growth. Crystals of 1-I (as 1-I·PF6·0.5EtOH) suitable for x-ray crystallography were grown by dissolving 1-3 mg of solids in ethanol (1 mL) and cooling solutions in a freezer at ca. 253 K. Crystals of 2-I (as 2-I·PF6) were grown in a similar manner in methanol.
X-ray crystallography. Diffraction data were collected on an Oxford Diffraction Gemini four-circle system with a Ruby CCD area detector. All structures were refined by full-matrix least squares against F 2 using SHELXL 97 and were solved by direct methods using SHELXS(TREF) with additional light atoms found by Fourier methods.
Hydrogen atoms were added at calculated positions and refined using a riding model. Blood serum stability assays. Human blood serum (900 µL) was combined with radio-tracer complex (100 µL, ~500 KBq). Samples were incubated at 310 K with 300
rpm stirring and analyzed after 1 h and 24 h by radio-HPLC. The serum samples were In vitro stability assays. MCF-7 cells were seeded in a 24-well plate using 1x10 6 per well. Cells were pre-incubated in drug free medium for 24 h at 310 K in a 5% CO2
humidified atmosphere. The medium was removed and fresh medium was added; 900 µL of medium combined with 100 µL radiotracer (~500 kBq). A second 24-well plate cells using a calibration curve (Fig. S6) . The data were processed using MS excel and standard deviations were calculated.
In vitro growth inhibition assay. Approximately 5000 A2780 or MCF-7 cells were seeded per well in 96-well plates. The cells were pre-incubated in drug-free media at 310 K for 48 h before adding various concentrations of the osmium complex. Cells were exposed to complexes for 24 h at 310 K. The supernatants were removed by suction and each well was washed with PBS. The cells were allowed to recover for 72 h in a drug-free medium at 310 K. The SRB assay was used to determine cell viability. Solutions of complexes (1 mM) were prepared in phosphate buffer solution (75 mM) with DEPMPO (6 mM) and H2O2 (10 mM). For complexes 1-I and 1-Cl, DMF (50%) was used to solubilise the complexes to 1 mM. The EPR spectra were recorded immediately after sample preparation. EPR spectra were analysed and simulated using the EASYSPIN software. [3] pKa determination. shifts of the peaks of complex 1-OH were followed by 1 H NMR. The pH* values were corrected using the equation; pH = 0.929pH* + 0.41, [4] and the data were fitted to the Henderson-Hasselbalch equation using Origin 8.5. [a] The retention times listed here were determined on a different HPLC column from that used in the main script. Figure S11 . HPLC chromatograms for complex 2-Cl (75 μM) after incubation with GSH (1 mol. equiv.) at 310 K in phosphate buffer (75 mM, pH 7.4) for various times. 
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